LZTR1 and neoplasm: Additionally, the c.353G>A likely pathogenic variant (VAF 5% and 38%) in the LZTR1 gene impairs RAS ubiquitination, leading to the deregulation of the RAS/MAPK pathway, which promotes proliferative signaling and contributes to subclonal tumor progression.